PD-L1 mRNA expression in patients with resectable gastric cancer and adenocarcinoma of the oesophago-gastric junction undergoing perioperative chemotherapy: Results from the FLOT4 phase III trial of the AIO.

被引：0
|
作者：
Waberer, Lisa
Homann, Nils
Wirtz, Ralph M.
Schmalenberg, Harald
Haag, Georg Martin
Schuler, Martin H.
Kasper, Stefan
Goetze, Thorsten Oliver
Pauligk, Claudia
Hofheinz, Ralf
Al-Batran, Salah-Eddin
机构：
[1] IKF GmbH Krankenhaus Nordwest, Frankfurt, Germany
[2] Acad Teaching Hosp Wolfsburg, Dept Internal Med 2, Wolfsburg, Germany
[3] STRATIFYER Mol Pathol GmbH, Cologne, Germany
[4] Krankenhaus Dresden Friedrichstadt, Med Klin 4, Dresden, Germany
[5] Univ Heidelberg Hosp, Dept Med Oncol, Natl Ctr Tumor Dis, Heidelberg, Germany
[6] Univ Hosp Essen, Essen, Germany
[7] UCT Univ Canc Ctr, Inst Clin Canc Res IKF, Krankenhaus Nordwest, Frankfurt, Germany
[8] Univ Mannheim, Mannheim, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e24277
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e24277
引用
收藏
页数：1
相关论文
共 50 条
  • [1] PD-L1 expression in gastric and gastroesophageal junction cancer patients treated with perioperative chemotherapy
    Ribeiro, Heber S. C.
    Menezes, Jacqueline N.
    da Costa Jr, Wilson L.
    de Jesus, Victor Hugo F.
    Diniz, Alessandro L.
    Godoy, Andre L.
    de Farias, Igor Correia
    Torres, Silvio M.
    Neotti, Tatiane
    Mello, Celso A. L.
    Begnami, Maria Dirlei F. S.
    Dias-Neto, Emmanuel
    Riechelmann, Rachel P.
    Fernandez Coimbra, Felipe Jose
    JOURNAL OF SURGICAL ONCOLOGY, 2022, 126 (01) : 150 - 160
  • [2] Docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) as perioperative treatment of resectable gastric or gastroesophageal junction adenocarcinoma: The multicenter, randomized phase 3 FLOT4 trial (German Gastric Group at AIO)
    Salah-Eddin, Al-Batran
    Claudia, Pauligk
    Nils, Homann
    Harald, Schmalenberg
    Hans-Georg, Kopp
    Martin, Haag Georg
    Barbara, Luley Kim
    Wolff, Schmiegel H.
    Gunnar, Folprecht
    Stephan, Probst
    Nicole, Prasnikar
    Peter, Thuss-Patience C.
    Jorg, Trojan
    Oliver, Goetze Thorsten
    Johannes, Meiler
    Martin, Schuler H.
    Elke, Jaeger
    Ralf-Dieter, Hofheinz
    ANNALS OF ONCOLOGY, 2017, 28
  • [3] Phase II trial of perioperative PD-L1 inhibition with avelumab and mDCF chemotherapy for resectable locally advanced gastric and esophago-gastric adenocarcinoma
    Alcindor, T.
    Awan, A.
    Opu, T.
    Asselah, J.
    Vanhuyse, M.
    Mueller, C.
    Ferri, L.
    ANNALS OF ONCOLOGY, 2018, 29
  • [4] Preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction type II/III adenocarcinoma: The phase III "PREVENT" trial of the AIO/CAOGI/ACO
    Bankstahl, U. S.
    Al-Batran, S-E.
    Piso, P.
    Lorenzen, S.
    Ostrzyzek, M.
    Pauligk, C.
    Habibzade, T.
    Schenk, M.
    Schlenska-Lange, A.
    Reim, D.
    Bechstein, W. O.
    Koenigsrainer, A.
    Moenig, S. P.
    Rau, B.
    Schwarzbach, M.
    Goetze, T. O.
    ANNALS OF ONCOLOGY, 2021, 32 : S1075 - S1075
  • [5] Preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction type II/III adenocarcinoma – the phase III “PREVENT”- (FLOT9) trial of the AIO /CAOGI /ACO
    Thorsten O. Götze
    Pompiliu Piso
    Sylvie Lorenzen
    Ulli S. Bankstahl
    Claudia Pauligk
    Moustafa Elshafei
    Giuseppe Amato
    Daniel Reim
    Wolf O. Bechstein
    Alfred Königsrainer
    Stefan P. Mönig
    Beate Rau
    Matthias Schwarzbach
    Salah-Eddin Al-Batran
    BMC Cancer, 21
  • [6] Preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction type II/III adenocarcinoma - the phase III "PREVENT"-(FLOT9) trial of the AIO/CAOGI /ACO
    Goetze, Thorsten O.
    Piso, Pompiliu
    Lorenzen, Sylvie
    Bankstahl, Ulli S.
    Pauligk, Claudia
    Elshafei, Moustafa
    Amato, Giuseppe
    Reim, Daniel
    Bechstein, Wolf O.
    Koenigsrainer, Alfred
    Moenig, Stefan P.
    Rau, Beate
    Schwarzbach, Matthias
    Al-Batran, Salah-Eddin
    BMC CANCER, 2021, 21 (01)
  • [7] Preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction type II/III adenocarcinoma: The phase III "PREVENT" trial of the AIO /CAOGI /ACO.
    Goetze, Thorsten Oliver
    Piso, Pompiliu
    Lorenzen, Sylvie
    Bankstahl, Ulli Simone
    Ostrzyzek, Marcin
    Pauligk, Claudia
    Habibzade, Timursah
    Reim, Daniel
    Bechstein, Wolf Otto
    Konigsrainer, Alfred
    Monig, Stefan Paul
    Rau, Beate
    Schwarzbach, Matthias
    Al-Batran, Salah-Eddin
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [8] Frequency of PD-L1 positivity and microsatellite instability (MSI) in the DANTE trial: Perioperative atezolizumab with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma. A randomized, open-label phase IIb trial of the German gastric group at the AIO and SAKK
    Kopp, C.
    Lorenzen, S.
    Gaiser, T.
    Thuss-Patience, P. C.
    Schenk, M.
    Lindig, U.
    Kretzschmar, A.
    Heuer, V.
    Goekkurt, E.
    Haag, G. M.
    Knorrenschild, J. Riera
    Bolling, C.
    Hofheinz, R. D.
    Siebenhuener, A. R.
    Irahara, N.
    Waberer, L.
    Pauligk, C.
    Gotze, T. O.
    Homann, N.
    Al-Batran, S-E.
    ANNALS OF ONCOLOGY, 2021, 32 : S1069 - S1070
  • [9] Docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) for resectable esophagogastric cancer: Updated results from multicenter, randomized phase 3 FLOT4-AIO trial (German Gastric Group at AIO)
    Al-Batran, S-E.
    Pauligk, C.
    Homann, N.
    Schmalenberg, H.
    Kopp, H-G.
    Haag, G. M.
    Luley, K.
    Folprecht, G.
    Probst, S.
    Thuss-Patience, P.
    Trojan, J.
    Koenigsmann, M.
    Lindig, U.
    Pohl, M.
    Kasper, S.
    Hler, M. Mo
    Goetze, T.
    Schuler, M.
    Jaeger, E.
    Hofheinz, R. D.
    ANNALS OF ONCOLOGY, 2017, 28
  • [10] Perioperative chemotherapy with docetaxel, oxaliplatin and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): a randomized, multicenter phase 3 trial
    Al-Batran, S. -E.
    Pauligk, C.
    Homann, N.
    Schmalenberg, H.
    Kopp, H. -G.
    Haag, G. M.
    Luley, K. B.
    Schmiegel, W.
    Folprecht, G.
    Probst, S.
    Prasnikar, N.
    Thuss-Patience, P.
    Fischbach, W.
    Trojan, J.
    Koenigsmann, M.
    Goetze, T. O.
    Kraus, T. W.
    Battmann, A.
    Moenig, S. P.
    Bechstein, W.
    Gaiser, T.
    Tannapfel, A.
    Jaeger, E.
    Schuler, M.
    Lindig, U.
    Pohl, M.
    Kasper, S.
    Moehler, M.
    Hofheinz, R. D.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 200 - +
12345